In this episode recorded live at the Reuters event in Barcelona, Nataliya Andreychuk sits down with Haider Alleg, pharma strategist turned venture capitalist at Allegory Capital, to explore why AI in pharma commercial operations is still mostly noise — and what it will actually take to change that.

With 20 years in pharma and a fresh perspective from the VC world, Haider cuts through the hype and makes a bold claim: this isn't a technology shift. It's a culture shift.

Key takeaways:

AI in R&D and manufacturing is already mature — commercial operations are just catching up

Dark factories and agentic systems show what full automation can look like

The biggest opportunity isn't automating tasks — it's re-internalizing operational work with AI

Medical and scientific affairs are best positioned to  ...